An interventional study of Lens-Exchange and Add-on in Age - Related Macular Degeneration (AMD), sponsored by VisionCare, Inc.. Recruiting at 12 sites in 3 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Macular Degeneration by VisionCare, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Macular Degeneration · VisionCare, Inc..
Among the 10 studies in Macular Degeneration by VisionCare, Inc., this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 9 with no phase, and was the 10th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →2 of the 10 studies in Macular Degeneration by VisionCare, Inc. are open now, in 4 countries. Recruiting first, the newest first:
VisionCare, Inc. · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 44 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 31 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
VisionCare, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
2 of the studies in Macular Degeneration by VisionCare, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07164378VisionCare, Inc.International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study | 2026-12-30 |
| NCT04796545VisionCare, Inc.Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Macular Degeneration by VisionCare, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment. This randomized, international, multicenter study will evaluate the safety and efficacy of the device in this patient group. Findings will support regulatory submissions, clinical decision-making, and potential label expansion.
Eligible AMD patients with existing IOL on both eyes will be randomized to either have the SING-IMT device placed on top of the existing IOL, or to replace the existing IOL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
13, Not a woman of (WOCBP): A WOCBP who agrees to follow guidance starting with the screening visit and through to the end of the study
Exclusion Criteria:
A. Bilateral Ocular Conditions (affecting both eyes):
Patient predisposing to eye rubbing
B. Surgical Eye Conditions:
Optic Nerve Disease
C. Systemic or Other General Conditions:
Any condition or situation that, in the opinion of the investigator, may:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SING IMT™ implantation in the sulcus after removal of the previously implanted IOL
Procedure: Lens-Exchange
SING IMT™ implantation in the sulcus in front of an existing IOL
Procedure: Add-on
The existing IOL will be removed and replaced by implanting SING IMT™ device in the sulcus
The SING IMT™ device will be placed in front of the existing IOL and implanted in the sulcus.
percentage of ECD loss
assessed within each treatment group relative to baseline (pre-surgery). The ECD loss should not exceed 23%
Time frame: at baseline, then at 1, 3 and 6 months
Incision size required for device implantation
measurement of the incision size
Time frame: baseline
Number of Surgical Complications, AEs and SAEs
Assess number of safety events comparing to similar procedures.
Time frame: at baseline, then at 1, 3 and 6 months
Acuity
Change in near and distance best corrected acuity in implanted eyes
Time frame: at baseline, then at 1, 3 and 6 months
Patient-reported outcomes
Using the Impact of Vision Impairment (IVI) questionnaire, 28 questions are answered, providing 4 different scores: 1. Vision-related quality of life Average of all items (ranging from 0 to 2.9) 2. Reading and accessing information Average of (Q1, Q3, Q5, Q6, Q7, Q8, Q9, Q14, Q15), (ranging from 0 to 2.7) 3. Mobility and Independence Average of (Q2, Q4, Q10, Q11, Q12, Q13, Q16, Q17, Q18, Q19, Q20), (ranging from 0 to 3) 4. Emotional well-being Average of (Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28), (ranging from 0 to 3)
Time frame: at baseline, then at 1, 3 and 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 133 interventional studies with no phase under Macular Degeneration, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VisionCare, Inc.